Xeris Pharmaceuticals Inc (XERS) - Net Assets
Based on the latest financial reports, Xeris Pharmaceuticals Inc (XERS) has net assets worth $13.01 Million USD as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($392.01 Million) and total liabilities ($379.00 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore Xeris Pharmaceuticals Inc balance sheet assets for the complete picture of this company's asset base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $13.01 Million |
| % of Total Assets | 3.32% |
| Annual Growth Rate | N/A |
| 5-Year Change | -85.63% |
| 10-Year Change | N/A |
| Growth Volatility | 251.55 |
Xeris Pharmaceuticals Inc - Net Assets Trend (2016–2025)
This chart illustrates how Xeris Pharmaceuticals Inc's net assets have evolved over time, based on quarterly financial data. Check how tangible is Xeris Pharmaceuticals Inc's equity to evaluate the tangible quality of the company's equity base.
Annual Net Assets for Xeris Pharmaceuticals Inc (2016–2025)
The table below shows the annual net assets of Xeris Pharmaceuticals Inc from 2016 to 2025. For live valuation and market cap data, see XERS market cap.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $13.69 Million | +146.22% |
| 2024-12-31 | $-29.61 Million | -336.67% |
| 2023-12-31 | $-6.78 Million | -115.01% |
| 2022-12-31 | $45.19 Million | -52.55% |
| 2021-12-31 | $95.23 Million | +559.68% |
| 2020-12-31 | $14.44 Million | 0.00% |
| 2019-12-31 | $14.44 Million | -80.86% |
| 2018-12-31 | $75.41 Million | +230.39% |
| 2017-12-31 | $-57.83 Million | -81.09% |
| 2016-12-31 | $-31.93 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Xeris Pharmaceuticals Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 63727600000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $17.00K | 0.12% |
| Other Comprehensive Income | $-25.00K | -0.18% |
| Other Components | $685.00 Million | 5004.05% |
| Total Equity | $13.69 Million | 100.00% |
Xeris Pharmaceuticals Inc Competitors by Market Cap
The table below lists competitors of Xeris Pharmaceuticals Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Kidswant Children Products Co.Ltd.
SHE:301078
|
$1.40 Billion |
|
Xian International Medical Investment Co Ltd
SHE:000516
|
$1.40 Billion |
|
Banvida
SN:BANVIDA
|
$1.40 Billion |
|
World Kinect Corporation
NYSE:WKC
|
$1.40 Billion |
|
Adapthealth Corp
NASDAQ:AHCO
|
$1.39 Billion |
|
Alrov Properties & Lodgings Ltd
TA:ALRPR
|
$1.39 Billion |
|
Hunan Zhongke Electric
SHE:300035
|
$1.39 Billion |
|
Monte Rosa Therapeutics Inc
NASDAQ:GLUE
|
$1.39 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Xeris Pharmaceuticals Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from -29,615,000 to 13,689,000, a change of 43,304,000.
- Net income of 554,000 contributed positively to equity growth.
- Share repurchases of 10,876,000 reduced equity.
- New share issuances of 9,167,000 increased equity.
- Other factors increased equity by 44,459,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $554.00K | +4.05% |
| Share Repurchases | $10.88 Million | -79.45% |
| Share Issuances | $9.17 Million | +66.97% |
| Other Changes | $44.46 Million | +324.78% |
| Total Change | $- | % |
Book Value vs Market Value Analysis
This analysis compares Xeris Pharmaceuticals Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 101.96x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2016-12-31 | $-17.33 | $8.08 | x |
| 2017-12-31 | $-28.51 | $8.08 | x |
| 2018-12-31 | $6.26 | $8.08 | x |
| 2019-12-31 | $0.55 | $8.08 | x |
| 2020-12-31 | $0.55 | $8.08 | x |
| 2021-12-31 | $1.21 | $8.08 | x |
| 2022-12-31 | $0.33 | $8.08 | x |
| 2023-12-31 | $-0.05 | $8.08 | x |
| 2024-12-31 | $-0.20 | $8.08 | x |
| 2025-12-31 | $0.08 | $8.08 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Xeris Pharmaceuticals Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 4.05%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.19%
- • Asset Turnover: 0.76x
- • Equity Multiplier: 28.02x
- Recent ROE (4.05%) is above the historical average (-215.38%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2016 | 0.00% | -1228.74% | 0.03x | 0.00x | $-10.02 Million |
| 2017 | 0.00% | -1706.56% | 0.03x | 0.00x | $-20.77 Million |
| 2018 | -79.68% | -2437.32% | 0.02x | 1.59x | $-67.62 Million |
| 2019 | -869.91% | -4613.52% | 0.02x | 7.55x | $-127.02 Million |
| 2020 | -869.91% | -4613.52% | 0.02x | 7.55x | $-127.02 Million |
| 2021 | -128.87% | -247.48% | 0.16x | 3.20x | $-132.25 Million |
| 2022 | -209.49% | -85.86% | 0.32x | 7.62x | $-99.18 Million |
| 2023 | 0.00% | -37.98% | 0.51x | 0.00x | $-61.58 Million |
| 2024 | 0.00% | -27.00% | 0.63x | 0.00x | $-51.87 Million |
| 2025 | 4.05% | 0.19% | 0.76x | 28.02x | $-814.90K |
Industry Comparison
This section compares Xeris Pharmaceuticals Inc's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $195,817,616
- Average return on equity (ROE) among peers: -66.14%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Xeris Pharmaceuticals Inc (XERS) | $13.01 Million | 0.00% | 29.13x | $1.39 Billion |
| Aurora Cannabis Inc (ACB) | $1.68 Million | -10.54% | 0.00x | $164.96 Million |
| Akanda Corp (AKAN) | $-5.03 Million | 0.00% | 0.00x | $2.84 Million |
| Akebia Ther (AKBA) | $635.93 Million | -27.03% | 0.57x | $340.21 Million |
| Alkermes Plc (ALKS) | $58.35 Million | -183.19% | 3.99x | $7.49 Billion |
| Amylyx Pharmaceuticals Inc (AMLX) | $-66.72 Million | 0.00% | 0.00x | $1.64 Billion |
| Amphastar P (AMPH) | $251.54 Million | 4.72% | 0.35x | $854.96 Million |
| Amneal Pharmaceuticals, Inc. Class A Common Stock (AMRX) | $61.30 Million | -137.01% | 55.65x | $5.21 Billion |
| Amneal Pharmaceuticals, Inc. Class A Common Stock (AMRX) | $896.36 Million | -18.93% | 3.86x | $3.57 Billion |
| Anika Therapeutics Inc (ANIK) | $108.93 Million | 10.79% | 0.30x | $196.52 Million |
| ANI Pharmaceuticals Inc (ANIP) | $15.83 Million | -300.23% | 1.30x | $1.78 Billion |
About Xeris Pharmaceuticals Inc
Xeris Biopharma Holdings, Inc., a commercial-stage biopharmaceutical company, engages in developing and commercializing therapies for chronic endocrine and neurological diseases in Illinois. It offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia in pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related … Read more